However, GLP-1 agonists were most likely to be associated with an adverse event compared to other interventions.<h4>Conclusion</h4>GLP-1 agonists may represent the most promising anti-diabetic treatment to reduce hepatic steatosis and liver enzyme activity in T2DM and NAFLD patients. This evidence concerns the gene GLP1R and fatty liver disease.